Gene structure information identified by combining Compugen's AI/ML predictive computational discovery platform, Unigen™ with Ultima's UG 100™ sequencing platform to better understand…
Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programsCAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE…
David Chemerow David Chemerow OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the…
Strategic Funding Led by Nimbus Synergies, Backed by Merck GHI, to Accelerate AI-Powered CollaborationsVANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE…
On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN)…
Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales…
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to…
Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technologyRUTHERFORD, N.J., Feb.…
Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing…
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- CompareNetworks is proud to announce the publication of the first issue of Cell…